Severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) /Hepatitis B virus (HBV) Co‐infected Patients: A case series and review of the literature

Bekçibaşı, Muhammed; Arslan, Eyüp

doi:10.1111/ijcp.14412

Cited by 10 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, COVID-19 also causes abnormal liver function and liver damage [ 8 ]. However, the results of previous studies are inconsistent on whether COVID-19 and HBV coinfection will increase the risk of death and critical illness [ 6 , 9 ]. Furthermore, some questions on this topic remain unresolved: (1) whether there is a difference in the risk of death/critical illness between different stages of HBV (resolved hepatitis B, HBeAg (−) CHB/infection, HBeAg (+) CHB/infection, and HBV reactivation) coinfection with COVID-19, and (2) if there is a difference, whether it is due to abnormal liver function and to what degree.…”

Section: Introductionmentioning

confidence: 99%

Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis

Yang

Wang

et al. 2022

Infect Dis Ther

View full text Add to dashboard Cite

Introduction This study aimed to determine whether there is a difference in the risk of death/critical illness between different stages of hepatitis B virus (HBV) (resolved hepatitis B, HBeAg (−) chronic hepatitis B [CHB]/infection, HBeAg (+) CHB/infection, and HBV reactivation) coinfected with coronavirus disease 2019 (COVID-19); and if there is a difference, whether it is due to abnormal liver function and to what extent. Methods This cohort study included all COVID-19 inpatients of a single-center tertiary care academic hospital in Wuhan, Hubei, China, between February 4, 2020, and follow-up to April 14, 2020. A total of 2899 patients with COVID-19 were included as participants in this study, and they were divided into five groups based on hepatitis B infection status. Follow-up was conducted for mortality and ICU admission during hospitalization. Results The median follow-up time was 39 days (IQR, 30–50), with 66 deaths and 126 ICU admissions. After adjustment, compared with patients without CHB, the hazard ratio (HR) for ICU admission was 1.86 (95% CI: 1.05–3.31) for patients with HBeAg (+) CHB/infection. The HR for death was 3.19 (95% CI: 1.62–6.25) for patients with HBeAg (+) CHB/infection. The results for the mediating effect indicated that the total effect of HBeAg (+) CHB/infection on death/ICU stay was partially mediated by abnormal liver function, which accounted for 79.60% and 73.53%, respectively. Conclusion Patients with COVID-19 coinfected with HBV at the HBeAg (+) CHB/infection stage have an increased risk of poor prognosis, and abnormal liver function partially mediates this increased risk of poor prognosis caused by the coinfection. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-022-00638-4.

show abstract

Section: Introductionmentioning

confidence: 99%

Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis

Yang

Wang

et al. 2022

Infect Dis Ther

View full text Add to dashboard Cite

show abstract

“…The association between adverse outcomes after COVID-19 and several other infectious diseases is studied. Although immune dysregulation is described in patients infected with both SARS-CoV-2 and HBV, a co-infection did not significantly affect the outcome of COVID-19 [12,32]. An association between past CMV infection and adverse outcomes after infection with SARS-CoV-2 is hypothesized through increase of inflammatory mediated cytokines in these patients [13,33], however, a direct association study has not been performed to this date.…”

Section: Discussionmentioning

confidence: 88%

No Influence of Previous Coxiella burnetii Infection on ICU Admission and Mortality in Emergency Department Patients Infected with SARS-CoV-2

Weehuizen

Spronsen

Hoepelman

et al. 2022

JCM

View full text Add to dashboard Cite

Background: the geographical similarities of the Dutch 2007–2010 Q fever outbreak and the start of the 2020 coronavirus disease 19 (COVID-19) outbreak in the Netherlands raised questions and provided a unique opportunity to study an association between Coxiella burnetii infection and the outcome following SARS-CoV-2 infection. Methods: We performed a retrospective cohort study in two Dutch hospitals. We assessed evidence of previous C. burnetii infection in COVID-19 patients diagnosed at the ED during the first COVID-19 wave and compared a combined outcome of in-hospital mortality and intensive care unit (ICU) admission using adjusted odds ratios (OR). Results: In total, 629 patients were included with a mean age of 68.0 years. Evidence of previous C. burnetii infection was found in 117 patients (18.6%). The combined primary outcome occurred in 40.2% and 40.4% of patients with and without evidence of previous C. burnetii infection respectively (adjusted OR of 0.926 (95% CI 0.605–1.416)). The adjusted OR of the secondary outcomes in-hospital mortality, ICU-admission and regular ward admission did not show an association either. Conclusion: no influence of previous C. burnetii infection on the risk of ICU admission and/or mortality for patients with COVID-19 presenting at the ED was observed.

show abstract

“…This meta-analysis included 40,502 patients, with sample sizes ranging from 28 to 19,160 [5,[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. These studies were mainly from 3 countries -China, Korea, and Turkey.…”

Section: Resultsmentioning

confidence: 99%

“…13 studies were included in the analysis [8,9,11,12,14,16,17,[19][20][21][22][23][24] to determine the impact of pre-existing HBV on the severity of COVID-19 patients. Our study found that pre-existing HBV greatly enhances the risk of developing to severe COVID-19 (OR = 1.90, I 2 = 44%, and 95% CI 1.62-2.24) (Figure 4).…”

Section: Pre-existing Hbv and The Severity Of Covid-19mentioning

confidence: 99%

The impact of HBV infection on clinical outcomes of COVID‐19 patients: a systematic review and meta-analysis

Guo¹,

Zeng²,

Li³

et al. 2023

Epidemiol. Infect.

View full text Add to dashboard Cite

The impact of hepatitis B virus (HBV) infection on clinical outcomes of coronavirus disease 2019 (COVID-19) remains unclear. The aim of this study is to explore this impact. For this systematic review and meta-analysis, we searched PubMed, Web of Science, Embase, Cochrane library, China National Knowledge Infrastructure (CKNI), China Science and Technology Journal Database (VIP), and Wan Fang database for articles between 1 January 2020 and 1 February 2023. We used the Newcastle–Ottawa Quality Assessment to evaluate the study’s quality. A random-effects meta-analysis was performed utilising the rates of severe/critical illness and death in COVID-19 patients with and without HBV infection. Eighteen studies with a total of 40,502 participants met the inclusion criteria. The meta-analysis showed that compared to those without HBV infection, COVID-19 patients with HBV were at increased risk of mortality (OR = 1.65, I2 = 58%, and 95% CI 1.08–2.53) and severity (OR = 1.90, I2 = 44%, and 95% CI 1.62–2.24). The region and gender may influence the outcomes of COVID-19 patients with HBV infection, but it requires more global data to confirm. In conclusion, HBV infection is significantly linked to an increased risk of severity and mortality in COVID-19.

show abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) /Hepatitis B virus (HBV) Co‐infected Patients: A case series and review of the literature

Cited by 10 publications

References 32 publications

Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis

Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis

No Influence of Previous Coxiella burnetii Infection on ICU Admission and Mortality in Emergency Department Patients Infected with SARS-CoV-2

The impact of HBV infection on clinical outcomes of COVID‐19 patients: a systematic review and meta-analysis

Contact Info

Product

Resources

About